TELESTA THERAPEUTICS INC T.TST

We shouldn't be in this position

[runningonempty]

I did not listen to committee meeting but in reading through good comments here and on Seeking Alpha by John Ford the overwhelming concensus is that TST management did a piss poor job in presenting there case. There are lots of comments on the meeting, but seems to come back that the company was not prepared or could not answer the questions asked of them. From the comments I have read the vote could have easliy gone in our favour had the company did a better job in answering questions about trial and data. Seems for whatever reason they were not properly prepared or thought this was a slam dunk. It's like they went to a gun fight with a knife.
It's too bad because we are now in a tough position and may never recover. people should be demanding answers from TST, not petitioning the FDA.
There is lots of talk about being approved by FDA in February, that will never happen unless TST gets more involved or serious and starts working with FDA to make this happen, otherwise we are fuk'd.

[DamnYankees]

I did listen and. TST was not anywhere near as prepared as they should have been. However, the merit of their submission, as related to the FDA a guidelines for approval was brushed under the carpet early on. It wasn't a fair fight. I felt like I was watching a court room trial where the DA was prosecuting a racketeering case and the defence was prepared to defend a public loitering charge

[investderp]

What are you upset about in terms of Telesta's panel "not being prepared"?   That they didn't, at the drop of a hat, answer what day of the week the 50th patient to undergo treatment with MCNA was born on?   That they couldn't read minds and have sub-group disease free survival data for only the odd numbered CIS patients, when arranged left to right from shortest

[DamnYankees]

Hey I think Miss Champaign did an admirable job in the circumstances. But there was a billion dollar plus opportunity, and a game changing treatment for BC patients  riding on that presentation and its merits that may have gone up in F&$@;g smoke. I don't know whether they needed more company representation or higher level executive support but they were not prepared for the pushback

[investderp]

I don't see the point of sending executives to the meeting.  As in, they are more likely than not further out of touch with the data and statistical analysis that was being asked of them than the experts that were sent.  They might be able to offer some sort of sweet talking, but I think Dr. O'Donnell did a pretty good job of selling it with his topic and closing remarks.  

[DamnYankees]

My own opinion is that you send your heavyweights to a decision of this magnitude. For posture and humanizing the efforts of the company if nothing else. I learned  long ago that big shots like to be sold to by bigshots. . O'Donnel  was compelling but I'm not sure that he was familiar with the insignificant mechanics of the trial that Adcomm members spent more than half their

[ragingbull1327]

I'm wishing they provided a clearer understanding as to why they called us to a meeting to discuss the drug, and then pick apart trial sizes, "how it works", if it's suitable as a primary treatment, and a dozen other things.  They already knew these numbers and THEY ALONE "FAST-TRACKED" the treatment.   Twice, to my knowledge.   Once prior to 2010 and

[davekin]

This post has been removed in accordance with Community Policy

[investderp]

[DamnYankees]

I fully understand the specific knowledge difference between the two, and I thought O'Donnel delivered as more or more than anyone, but having your CEO, who also happens to be Chief Clinical Officer is not a negative, particularly given Berendt's background of success with the FDA. I am sure Monique C is capably knowledgeable, but that was an aggressive, even hostile environment and at

[ragingbull1327]

Considering it wasn't in front of a judge that apparently matters or it would have been D-day, I'll take the meeting at face value.   A good discussion, but mostly Irrelevant in the approval process, because MCNA has much broader therapeutic use than just what the vote was about.....